GSK's India arm reports 12.5 percent Q2 profit at Rs 218 crore

Published On 2023-11-13 07:15 GMT   |   Update On 2023-11-14 11:58 GMT
Advertisement

Bengaluru: GlaxoSmithKline Pharmaceuticals reported a 12.5% rise in quarterly profit as the Indian unit of UK's GSK plc saw strong demand for its vaccines and general medicine.

Consolidated profit for the quarter ended September 30 rose to Rs 218 crore ($26.18 million) from Rs 193 crore a year earlier.
Sales of general medicine grew 5% during the quarter, while those of vaccines rose 10% led by demand for its shingles vaccine, Shingrix, the company said in a statement.
Advertisement
Revenue from operations rose 4.4% to Rs 957 crore. Cost of materials consumed fell 31.2% during the quarter.
"We held leadership position for our key brands in relevant therapy areas such as anti-infectives and dermatology," said Bhushan Akshikar, managing director of GSK India.
GSK raised its full-year profit and sales guidance for the second time after its third-quarter earnings beat expectations earlier this month. The raise in forecast is following the strong launch of its respiratory syncytial virus (RSV) vaccine in the United States.
Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News